18F-FTC-146 PET/CT in Newly-Diagnosed Osteosarcoma

• Status: Recruiting
• Trial end date: 2022-07-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this research is to evaluate the study drug, 18F FTC-146, as a positron emission tomography (PET) / computed tomography (CT) radiotracer imaging agent to evaluate tumor status in patients newly diagnosed with osteosarcoma ("bone cancer").

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Stanford University

Criteria

Inclusion Criteria:

• Patients with biopsy proven osteosarcoma requiring local surgical intervention.

• ECOG ≤ 2

• Ability to understand and the willingness to sign a written informed consent document.

Exclusion Criteria:

• Chemotherapy in the past 2 months.

• Prior history of allergic reaction to 18F FTC 146.

• Pregnant or nursing